• 30 January 2019

    ENT therapies: a wave of first-in-class innovation

    Globally, there are 9,052 marketed products for ENT disorders. Most of these pharmaceuticals are small molecules and generics that target G protein-coupled receptors (GPCRs), nuclear receptors, and microbial membranes.

  • 2 November 2018

    EC approves Vertex’s Symkevi for cystic fibrosis

    The European Commission has approved London-based Vertex’s Symkevi (ivacaftor+tezacaftor) in combination with ivacaftor for patients with specific mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Go Top